#USA #San Diego #gene therapy #Advisors #Navega Therapeutics

Navega Therapeutics Welcomes New Strategic Advisors

Navega Therapeutics, a frontrunner in the field of epigenetic gene therapy, is thrilled to announce the appointment of four experienced individuals to its Board of Advisors. This strategic move aims to bolster the company’s expertise in gene therapy product development, industry manufacturing, and business strategies as it positions itself for future growth.

The newly appointed advisors bring a wealth of experience and insight to the company, boasting over 125 years of cumulative expertise. Among them is Jeffrey M. Ostrove, Ph.D., a seasoned entrepreneur known for co-founding eight biotech companies. Currently serving on the Boards of three biotech firms, Dr. Ostrove is the Co-Founder, President, and Director of Papillon Therapeutics, which focuses on genetic treatments for rare diseases. He has a rich history in the industry, having previously been the CEO of multiple successful companies, including Stelios Therapeutics and Ceregene, which specialized in therapies for cardiac and neurodegenerative conditions.

Joining him is Chris Mason, MD, Ph.D., who carries over 30 years of extensive experience in cell and gene therapies. He is known for founding OriBiotech and serving in other key roles within various organizations involved in gene therapy. His academic contributions as a Full Professor at University College London supplement his extensive editorial experience with the journal 'Cell and Gene Therapy Insights'. He expresses keen excitement about Navega’s mission, particularly highlight its potential to offer significant relief to chronic pain patients without the severe side effects associated with opioids.

Daniel Bradbury, the former President and CEO of Amylin Pharmaceuticals, joins this distinguished group as well. His leadership in developing drug candidates for serious metabolic diseases led to the acquisition of Amylin by Bristol-Myers Squibb for a whopping $7.1 billion. His successful tenure in drug development strategy and marketing strengthens Navega's operational capabilities and market reach.

Alongside them is Diego Miralles, MD, whose impressive track record in biotechnology includes leadership roles at Laronde and Vividion Therapeutics. His experience spans clinical development phases and significant fundraising, which will be instrumental as Navega continues to raise capital to fund its innovative research initiatives.

Dr. Ana Moreno, the CEO of Navega Therapeutics, shared her enthusiasm regarding the newly appointed advisors, highlighting their deep insights into gene therapy and business strategies. She believes that such expertise will be invaluable as the company proceeds with the clinical development of its lead program, NT-Z001. Supported by recent funding from the National Institutes of Health and a $4 million grant from the California Institute for Regenerative Medicine, Navega has made impressive strides in a capital-efficient manner.

Navega Therapeutics focuses on pioneering epigenetic gene therapies targeting chronic pain and other complex conditions through an advanced AI-enabled platform. Its cutting-edge approach aims to modify gene expression for pain management, specifically targeting the NaV1.7 sodium channel at the DNA level. As the prospect of a non-addictive gene therapy emerges, Navega is positioning itself to redefine the treatment landscape for chronic pain conditions, offering hope to millions of patients seeking effective therapies without the risks of traditional opioid medications.

With the addition of these eminent advisors, Navega Therapeutics aims to accelerate the development of their innovative therapies, driving forward the potential for groundbreaking advances in patient care and treatment efficacy.

Summary

Navega Therapeutics stands at the forefront of change in the field of gene therapy with its latest strategic appointments, enhancing its capabilities and paving the way for innovation in the treatment of chronic pain.